Presentation and Panel Participation at Adelaide Capital Event on April 23
MISSISSAUGA, CANADA, April 21, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it will be participating in the “Virtual COVID & Healthcare Mini Conference” being hosted by Adelaide Capital on April 23 from 12:00-5:00 PM ET.
The conference will showcase the contributions that Canadian companies are making to help fight the coronavirus pandemic. Microbix will be discussing its longstanding work in providing the biological core of many existing diagnostic tests for infectious diseases, including for multiple respiratory viruses and bacteria. Additionally, Microbix will discuss how its Quality Assessment Products (QAPs™) can help ensure the accuracy of diagnostic tests, including tests for respiratory viruses and, in particular, about its important new REDx™FLOQ® SARS-CoV-2 swab-based and REDx™ SARS-CoV-2 liquid-format QAPs.
The conference will consist of a series of 20-minute corporate presentations, a panel discussion of critical pandemic-related issues, and a keynote presentation by Mr. Eden Rahim of Next Edge Capital. Mr. Rahim is a highly-respected life-sciences portfolio manager and his presentation at the conference is entitled, “Signal from the Noise: A compass to finding COVID-19 investment opportunities.”
To attend the Virtual COVID & Healthcare Mini Conference, RSVP via hyperlink (here), or by inputting https://zoom.us/webinar/register/WN_rbV3mis6RIyQG7WFVTx2cA into your browser. The conference will also be live streamed to Adelaide Capital’s YouTube Channel (here) and a replay will also be posted. Recently, information about Microbix has been posted to the Adelaide Capital YouTube Channel and the Microbix website, including an interview on COVID-19 QAPs with Ken Hughes, COO of Microbix, and a CEO corporate Webinar presentation.
Kindly note that the conference is in support of the HandSan Project. The HandSan Project is providing free 50 to 80 mL bottles of 70 to 80% ethanol hand sanitizer to high-need individuals in the Ottawa area. Further information about the HandSan Project is available from https://handsan.ca/
Adelaide Capital is a full-service Investor Relations firm that provides a unique and powerful perspective on Canadian public companies and a re-engineered business model. Adelaide’s extensive capital markets experience allows it to go deeper, strategically assessing each client and tailoring a plan that charts the best path to business success as a publicly-listed company. Specializing in small and mid-capitalization companies, its offerings are enhanced by a truly formidable factor – personal relationships with an extensive and deeply-valued network of investors across North America and around the world.
About Microbix Biosystems
Microbix develops proprietary biological and technology solutions for human health and well-being, with approximately 80 skilled employees and sales now usually exceeding $1 million per month on average. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure quality control of clinical diagnostic tests. Microbix antigens and QAPs are sold to many customers worldwide, at present primarily to multinational diagnostics companies and laboratory accreditation organizations.
Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots.
Microbix is a publicly-traded company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada.
This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of AdCap, Next Edge, HandSan, or the conference, the COVID-19 QAPs, the utility or consequences of use of the COVID-19 QAPs, references to external collaborators and regulatory processes, Microbix’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.
Please visit www.microb.wpengine.com or www.sedar.com for recent Microbix news and filings.
For further information, please contact Microbix at:
|Cameron Groome, CEO
|Jim Currie, CFO
|Deborah Honig, Investor Relations
Adelaide Capital Markets
(647) 203-8793 firstname.lastname@example.org